ILC Therapeutics, a Glasgow, Scotland-based biotechnology company, raised £3.5M in Pre-IPO funding.
The round was led by Robert Kopple with participation from Eos Angel Investment Syndicate, Scottish Enterprise and ILCT management.
Led by CEO Dr Alan Walker, ILC Therapeutics is a biotechnology company focused on modulating the innate immune system through the design and development of novel hybrid interferon drug candidates.
The company intends to use the funds to accelerate development of Alfacyte – its lead hybrid interferon designed to combat viral infections including Covid.
Alfacyte™ is ILCT’s lead Hybrid interferon drug candidate and is being developed as an inhaled medicine to treat Respiratory Viral Infections (RVIs) including SARS CoV-2. Its Hybrid Interferons are designed by identifying selected favourable attributes of naturally occurring interferon subtypes and combining them together in a new class of novel Hybrid Interferons. They are designed to provide enhanced efficacy and improved safety in comparison to their natural interferon subtypes.
The company was founded by Prof. W. H. Stimson FRSE, who established the Department of Immunology at The University of Strathclyde.
FinSMEs
07/09/2021